Access to Information Requests Completed - February 2012

The following is a list of Access to Information requests processed by Health Canada. The list is not all-inclusive. The list contains requests completed for which documents have been retrieved or treated. The list is provided in chronological order, by month and year, and by request number. (Requests focusing on personal information or third party proprietary information are not included.)

If you wish to obtain a copy of the records released in response to these requests informally, you may contact the Access to Information and Privacy Division.

Completed Requests

For the month of February 2012

Request #	Summary of Requests	Status of Completed Request	Number of Pages Disclosed
A-2009-00579	Copies of test results on the quality and management of drinking water aboard passenger trains, ferries, cruise ships and airplanes for the 2005-2009 trading period in Canada. (Quebec region only).	Disclosed in part	197
A-2010-00173	All documents regarding investigations into suspected counterfeit products.	Disclosed in part	433
A-2010-00751	Information regarding NPN 80012914 by Essiac Canada International.	Disclosed in part	516
A-2010-00923	All documents that enabled Health Canada officials to obtain the conclusion regarding complaint 51969, according to the provisions outlined in the Health Canada document: Guidance to Industry - How to Submit a Trade Complaint GUI-0038. (Jul 7, 2009 to Apr 22, 2010).	Disclosed in part	214
A-2010-01194	All documents from 2010 relating to the Strategic Policy Branch's commitment to consider conducting further analysis and monitoring activities as they relate to Infoway projects and related cash flow requirements.	All disclosed	178
A-2010-01346	Any memorandum, email from Health Canada representatives with respect to any adverse reactions or any adverse reaction reports in connection with CITALOPRAM. (Jan 09, 2011 to Feb 23, 2011).	Disclosed in part	138
A-2010-01417	All documents that allowed the registration of Valtrex (GlaxoSmithKline Inc.).	Disclosed in part	1,038
A-2010-01494	Information in the possession of the Ministry relating to the investigation by Sheila Weatherill of the 2008 listeria outbreak.	Disclosed in part	223
A-2010-01597	Information regarding the product Allopurinol.	Disclosed in part	44
A-2010-01602	Information regarding the product GILENYA, DIN 02365480 by NOVARTIS PHARMACEUTICALS CANADA INC.	Disclosed in part	318
A-2011-00028	All Question Period notes for the following:18-Jan-2011 ▪ PHTHALATES IN CONSUMER PRODUCTS AND COSMETICS14-Dec-2010 ▪ FOLIC-ACID FORTICATION ▪ CADMIUM IN FOOD ▪ CANADIAN MEDICAL ASSOCIATION - HEALTH ACCORD ▪ CANADIAN MEDICAL ASSOCIATION - PUBLIC DIALOGUE ▪ FORMALDEHYDE IN PRODUCTS ▪ INTERNAL AUDIT OF EMERGENCY PREPAREDNESS AND RESPONSE13-Dec-2010 ▪ CONSUMER SAFETY - CELL PHONES, CORDLESS PHONES, CELL PHONE TOWERS AND WI-FI SYSTEMS ▪ CURRENT STATUS OF THE TOBACCO LABELLING RENEWAL INITIATIVE10-Dec-2010 ▪ CURRENT STATUS OF THE TOBACCO LABELLING RENEWAL INITIATIVE08-Dec-2010 ▪ ASBESTOS-CHRYSOTILE ▪ CURRENT STATUS OF THE TOBACCO LABELLING RENEWAL INITIATIVE ▪ PATENTED MEDICINES - INVESTMENTS IN RESEARCH	All disclosed	56
A-2011-00029	Information regarding the product PENNSAID by Paladin Labs Inc.	Disclosed in part	116
A-2011-00108	All documentation pertaining to project or program funding agreements with and subsequent deliverables to Health Canada by Canadian Council on Tobacco Control.	Disclosed in part	1,533
A-2011-00152	Information regarding the product Metamucil Fibre Therapy Capsules, NPN 02247034 by Procter and Gamble Inc.	Disclosed in part	45
A-2011-00174	AERs. Report numbers: 000120187, 000120441, 000128352, 000138417, 000143933, 000145054, 000145059, 000147390, 000154944, 000155538 and 000157004.	Disclosed in part	40
A-2011-00193	AERs. Report numbers: 000193450, 000193558, 000193707, 000194109, 000194601, 000194760, 000195195, 000195196, 000195471 and 000195738.	Disclosed in part	84
A-2011-00320	AERs for the product Buckley's. Report numbers: 000184729, 000185977, 000216498, 000221169, 000221175, 000221310, 000226624, 000305080, 000314604, 000319304, 000327226, 000331758, 000335989, 000338272 and 000339230.	Disclosed in part	2
A-2011-00340	Information regarding the product Jamp-Fer, NPN 80024232 by JAMP Pharma Corporation.	Disclosed in part	38
A-2011-00344	Information regarding the product BYETTA, DINs 02361809 and 02361817 by ELI LILLY CANADA INC.	Disclosed in part	1
A-2011-00428	Information regarding the product Jamp - K 20, NPN 80013007 by JAMP Pharma Corporation.	Disclosed in part	77
A-2011-00430	Information relating to the following studies: 1) Emerging contaminants in house dust 2) Exposure study of CMP/CEPA chemicals 3) Exposure to particulate bound metals 4) Freshwater toxins 5) Investigation of children's exposure to chemicals in indoor dust 6) National Survey of disinfection by-products and selected emerging contaminants in Canadian drinking water 7) The Effects of Emissions from Petroleum Refineries on the Exacerbation of Adverse Health Effects among Asthmatic Children	All disclosed	8
A-2011-00482	All documents regarding Bayer CropScience relating to the preparation of the table entitled Studies Bayer CropScience Canada Inc's Sencor (Technical Herbicide (Nov 25, 2010) & 75 DF Herbicide (Dec 13, 2010)) Database Eligible for Compensable Protection Status provided to United Phosphorous, Inc.	Disclosed in part	285
A-2011-00500	AERs for the product Clopixol. Report number: 000361961.	Disclosed in part	10
A-2011-00664	All documents regarding Long-term & Elder Care between First Nations & Inuit Health and Whitebear First Nation. (Jan 1, 2008 to Dec 31, 2009).	Disclosed in part	176
A-2011-00685	Information regarding the product PROPOFOL INJECTION, DIN 02241504 by NOVOPHARM LIMITED.	Disclosed in part	693
A-2011-00687	Information regarding the product PROPOFOL INJECTION, DIN 02236887 by HOSPIRA HEALTHCARE CORPORATION.	Disclosed in part	507
A-2011-00705	Information regarding the product Lucentis by Novartis Pharmaceuticals Canada Inc.	Disclosed in part	263
A-2011-00763	All information pertaining to medical device reports involving the company/manufacturer Septodont. (Jan 1, 2001 to Oct 12, 2011).	Disclosed in part	13
A-2011-00798	Information regarding the product Vitamin D3, NPNs 80025598, 80025601, 80025606 and 80025610.	Disclosed in part	74
A-2011-00814	Information regarding the sales of pesticides across the country (by province) per year since the Pest Management Regulatory Agency RA) started collecting this information.	No records exist	0
A-2011-00837	AERs for the product beta-alanine. Report numbers: 000331118, 000344771, 000354462 and 000368560.	Disclosed in part	16
A-2011-00870	The most recent transition briefing books created for the Minister by Health Canada.	Disclosed in part	301
A-2011-00901	All clinical study data and literature references which allowed the licensing of SAVVY Long PTA Dilatation Catheter, including comments between Health Canada and the sponsor Clearstream Technologies LTD.	Disclosed in part	112
A-2011-00903	All documents about the release of the Expert Panel report on Energy Drinks. (Sep 1, 2011 to Oct 12, 2011).	Disclosed in part	336
A-2011-00905	All e-mails (including any and all attachments) to/from Chris Turner (Director General, Marketed Health Products Directorate) about energy drinks from Nov 1, 2010 to March 31, 2011	Disclosed in part	56
A-2011-00908	AERs. Report numbers: 000354641, 000356467, 000352343, 000352007, 000350647 and 000352952.	Disclosed in part	22
A-2011-00957	Information regarding the product Nicotine Lozenges 1mg / Thrive Lozenges 1mg, NPN 80007461 by Novartis Consumer Health Canada Inc.	Disclosed in part	57
A-2011-00971	All case files related to fraudulent travel claims and over reported leave of absence, which resulted in a loss of $63,714, as referenced in the 2011-11 Public Accounts of Canada.	Disclosed in part	77
A-2011-00972	All case files related to false or fraudulent claims for contributions, which resulted in a loss of $260,827, as referenced in the 2011-11 Public Accounts of Canada.	Disclosed in part	71
A-2011-00974	All case files related to unsolicited goods delivered and charged to acquisition card without approval, which resulted in a loss of $2,871, as referenced in the 2011-11 Public Accounts of Canada.	Disclosed in part	460
A-2011-00975	All communications regarding NHP Consulting Inc. by Mr. Scott Sawler, Sarah O'Connor, Stephanie De Silva, Adam Gibson, Gabriel Frost, or Maggie Graham. (Apr 1, 2011 to Nov 3, 2011).	Disclosed in part	39
A-2011-01050	Copy of the employment contract for the Chief Dental Officer.	Disclosed in part	24
A-2011-01061	Information regarding the product Good For You Royal Jelly 1000 Mg Softgel, NPN 80019684 by Good For You Corp.	Disclosed in part	174
A-2011-01062	Information regarding the product Royal Jelly, NPN 80024087 by Flora Manufacturing & Distributing Ltd.	Disclosed in part	52
A-2011-01065	Information regarding the product Thyrolift, NPN 80026859 by Darwen Holdings Ltd.	Disclosed in part	240
A-2011-01066	Information regarding the product Thyrosense, NPN 80028056 by Preferred Nutrition Inc.	Disclosed in part	90
A-2011-01070	All correspondence between the Government of Canada and any group in respect of the Federal Tobacco Control Strategy. (Jan 1, 2011 to Nov 9, 2011).	Disclosed in part	121
A-2011-01132	AERs. Report numbers: 000354462, 000367802 and 000367803.	Disclosed in part	11
A-2011-01194	All documents pertaining to Health Canada's policy regarding the test and retesting of current and former employees for Simian Foamy Virus.	All disclosed	123
A-2011-01196	All documents regarding the false positive and false negative rates for the Simian Foamy Virus.	Disclosed in part	24
A-2011-01216	All documents regarding the Nitro mg sample (purchased at Health Food store in Windsor, Ontario) tested for controlled substance methyl-l-testosterone.	Disclosed in part	26
A-2011-01278	Copy of the most recently compiled list of First Nations communities with drinking water advisories.	All disclosed	180
A-2011-01279	Information regarding the product PHARMA-D 50000 IU, DIN 02371502 by Pharmascience Inc.	Disclosed in part	84
A-2011-01282	AER for the product Alvesco (ciclesonide). Report number: 000376670.	Disclosed in part	1
A-2011-01283	AERs for the product Pantoloc (pantopraole sodium). Report numbers: 000374453 and 000377090.	Disclosed in part	16
A-2011-01284	AERs for the product Tecta (pantoprazole magnesium). Report numbers: 000375353, 000376634, 000377046, 000378475, 000379095 and 000379104.	Disclosed in part	6
A-2011-01285	All call-ups processed by this institution in the National Capital Region under the terms of the ANY Standing Offer or Supply Arrangement for Temporary Help Services during the period of December 2011.	Disclosed in part	48
A-2011-01286	All local purchase orders processed by this institution in the National Capital Region for the procurement of Temporary Help Services during the period of December 2011.	No records exist	0
A-2011-01287	Documentation which indicates all appointments term and casual employees by this institution in the National Capital Region under the term of the Public Service Employment Act during December 2011.	All disclosed	1
A-2011-01289	All call-ups and amendments issued under the terms of the TBIPS Standing Offer (EN578-055605) in the National Capital Region during the month of December 2011.	No records exist	0
A-2011-01292	A listing of the Access to Information requests submitted to Health Canada. (Dec 1, 2011 to Dec 31, 2011).	Disclosed in part	30
A-2011-01296	All documents of the second Cross Canada Survey of Radon Concentrations in Homes.	All disclosed	169
A-2011-01311	AERs for the product Fluviral. Report numbers: 000385578, 000386488, 000390463, 000390465, 000390467, 000390468, 000390473, 000390475, 000390476, 000390581, 000390589 and 000390595.	Disclosed in part	22
A-2011-01320	AERs for the product Aleve. Report numbers: 000373585, 000377021, 000377236, 000377934 and 000379077.	Disclosed in part	7
A-2011-01325	AER for the product Canesoral. Report number: 000377315.	Disclosed in part	2
A-2011-01328	AER for the product Adalat XL. Report number: 000377567.	Disclosed in part	1
A-2011-01329	AERs for the product Avelox. Report numbers: 000375913, 000375925, 000376681, 000377600 and 000377719.	Disclosed in part	7
A-2011-01330	AER for the product Angeliq. Report number: 000375862.	Disclosed in part	2
A-2011-01331	AER for the product Diane 35. Report number: 000375899.	Disclosed in part	1
A-2011-01332	AERs for the product Yaz. Report numbers: 000376198, 000376388 and 000377190.	Disclosed in part	3
A-2011-01333	AER for the product Xarelto. Report number: 000377102.	Disclosed in part	2
A-2011-01334	AERs for the product Magnevist. Report numbers: 000375809 and 000376675.	Disclosed in part	2
A-2011-01339	All reports (not released publicly) on threats posed by contaminated food or drugs imported from China. (Jan 14, 2011 to Jan 13, 2012).	No records exist	0
A-2011-01346	Documents related to prebiotics with the following brand 'Heinz'. (Jan 1, 2008 to Jan 16, 2012).	No records exist	0
A-2011-01347	Documents related to prebiotics with the following brand 'Enfamil'. (Jan 1, 2008 to Jan 16, 2012).	No records exist	0
A-2011-01349	Documents related to prebiotics with the following brand 'Kirkland'. (Jan 1, 2008 to Jan 16, 2012).	No records exist	0
A-2011-01350	Documents related to prebiotics with the following brand 'Life'. (Jan 1, 2008 to Jan 16, 2012).	No records exist	0
A-2011-01354	Information regarding the product Halaven.	All exempted	0
A-2011-01385	AER for the product Lupron. Report number: 000367678.	Disclosed in part	2
A-2011-01389	All recommendation reports for projects submitted by provincial and territorial governments under the Internationally Trained Worker Initiative.	All disclosed	73
A-2011-01390	All documents about gifts for HRH the Duke of Cambridge or the Duchess of Cambridge for their 2011 Canada tour. (Jan 1, 2011 to Jul 11, 2011).	No records exist	0
A-2011-01391	The nutritional guidelines of Health Canada for a Regular diet & Low Fat diet for an adult male living a sedentary lifestyle; age 60 years.	All disclosed	87
A-2011-01394	All documents related to the quantity of pesticides used in Canada annually. (Jan 1, 2006 to Jan 26, 2012).	Disclosed in part	6,418
A-2011-01395	Report of losses and thefts of Oxycontin. (Jan 1, 2011 to Dec 31, 2011).	All disclosed	52
A-2011-01396	Report of losses and thefts of Fentanyl. (Jan 1, 2011 to Dec 31, 2011).	All disclosed	14
A-2011-01397	Report of losses and thefts of hydromorphone. (Jan 1, 2011 to Dec 31, 2011).	All disclosed	55
A-2011-01398	Report of losses and thefts of methadone. (Jan 1, 2011 to Dec 31, 2011).	All disclosed	9
A-2011-01399	Report of losses and thefts of buprenorphine. (Jan 1, 2011 to Dec 31, 2011).	All disclosed	3
A-2011-01400	Report of losses and thefts of codeine. (Jan 1, 2011 to Dec 31, 2011).	All disclosed	51
A-2011-01405	AERs. Report numbers: 000340333, 000353898, 000334708, 000349151, 000338036, 000352009, 000345089, 000341280, 000341644 and 00035810.	Disclosed in part	17
A-2011-01448	AERs for the product Kaletra. Report numbers: 000368522 and 000368536.	Disclosed in part	4
A-2011-01450	Listing of all consultants hired who worked on the Canadian Guidelines for Wind Turbines.	No records exist	0
A-2011-01504	AER for the product Clopixol. Report number: 000376878.	Disclosed in part	1
A-2011-01505	AER for the product Sabril. Report number: 000378071.	Disclosed in part	2
A-2011-01506	Number of SAP releases for the following drug for the month of January 2012: Treanda.	All disclosed	1
A-2011-01507	Number of SAP releases for the following drug for the month of January 2012: Targretin.	All disclosed	1
A-2011-01508	Number of SAP releases for the following drug for the month of January 2012: Dacogen.	All disclosed	1
A-2011-01509	Number of SAP releases for the following drug for the month of January 2012: Carfilzomib.	No records exist	0
A-2011-01510	Number of SAP releases for the following drug for the month of January 2012: Folotyn.	All disclosed	1
A-2011-01511	Number of SAP releases for the following drug for the month of January 2012: Zolinza.	No records exist	0
A-2011-01512	Number of SAP releases for the following drug for the month of January 2012: Afatinib.	All disclosed	1
A-2011-01513	Number of SAP releases for the following drug for the month of January 2012: Prochymal.	No records exist	0
A-2011-01514	Number of SAP releases for the following drug for the month of January 2012: Halaven.	All disclosed	1
A-2011-01515	Number of SAP releases for the following drug for the month of January 2012: Cabazitaxel.	No records exist	0
A-2011-01516	Number of SAP releases for the following drug for the month of January 2012: Belinostat.	All disclosed	1
A-2011-01517	Number of SAP releases for the following drug for the month of January 2012: Campath	No records exist	0
A-2011-01520	Number of SAP releases for the following drug for the month of January 2012: Feraheme.	No records exist	0
A-2011-01521	Number of SAP releases for the following drug for the month of January 2012: Bendamustine.	All disclosed	1
A-2011-01522	Number of SAP releases for the following drug for the month of January 2012: Brentuximab.	All disclosed	1
A-2011-01540	Information regarding the product CO Memantine, DINs 02324059 and 02324067 by Cobalt Pharmaceuticals Company.	All exempted	0
A-2011-01551	All documents related to evidence of claims of safety and efficacy of Tamiflu. (Jan 7, 2012 to Feb 16, 2012).	No records exist	0
A-2011-01579	All documents related to drugs that have been bought and had to be discarded and or destroyed or because they are outdated or of poor quality. (Jan 1, 2000 to Feb 23, 2012).	No records exist	0